An approach to assess quality of life through biometric monitoring in cancer patients

Cancer is a serious disease that causes significant disability and suffering, so naturally Health Related Quality of Life (HRQoL) is a major concern of patients, families and clinicians. This paper intends to relate biometric indices, in terms of HRV metrics, with self-perceived HRQoL from patients with lymphoma. Patients (N = 12) answered FACT questionnaire and used a smartband that collected biometrical data in real-time along the chemotherapy treatment. Our results revealed that Physical Well-Being, Total, Lymphoma subscale and FACT-Lym Trial Outcome domains seem to have a similar pattern that HRV metrics across the treatment cycles. In specific, the FACT domains and the HRV metrics have the lowest average levels on the first cycle and seem to increase along the following cycles (3rd and 6th cycles). This approach of continuous assessment of HRQoL will enable a better accuracy and more supported clinical decision.QVida+: Estimação Contínua de Qualidade de Vida para Auxílio Eficaz à Decisão Clínica, funded by European Structural funds (FEDER-003446), supported by Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 202

A practical synthesis of the 13C/15N-labelled tripeptide N-formyl-Met-Leu-Phe, useful as a reference in solid-state NMR spectroscopy

A mild synthetic method for N-formyl-Met-Leu-Phe-OH (1) is described. After Fmoc solid phase peptide synthesis, on-bead formylation and HPLC purification, more than 30 mg of the fully 13C/15N-labelled tripeptide 1 could be isolated in a typical batch. This peptide can be easily crystallised and is therefore well suited as a standard sample for setting up solid-state NMR experiments